CUV Clinuvel shares dip, even as CEO comes back from temp leave After Clinuvel's (ASX:CUV) CEO Dr. Philippe Wolgen took time off back in March to respond to an "acute medical condition," it wasn't... Jonathon Davidson 1 day ago ASX News Healthcare Biotechnology
FRE Study spruiks Firebrick's Nasodine spray as 'effective treatment for common cold' A long-run study looking into leading Firebrick Pharma (ASX:FRE) product Nasodine has suggested the nasal spray can be an effective treatment for the common cold following a dive into the company’s Phase III trials.Listen to the HotCopper podcast for in-depth discussions and insig... Isaac McIntyre 4 days ago ASX News Healthcare Biotechnology
PIQ Proteomics claims it can diagnose throat cancer with blood test Proteomics International (ASX:PIQ) has popped +6% after reporting the "high accuracy" of its blood test for throat cancer. Jonathon Davidson 05 Jun 2025 13:24 (AEST) ASX News Healthcare Biotechnology
RCE 'Critical step': Go for Recce's Phase III trials after banking $15.8M in capital raise Recce Pharmaceuticals (ASX:RCE) has successfully filled its coffers ahead of its Phase III clinical trials in Indonesia and Australia, with the company this week landing @firm commitments” to place the full shortfall in its capital raise.Listen to the HotCopper podcast for i... Isaac McIntyre 04 Jun 2025 09:29 (AEST) ASX News Healthcare Biotechnology
PAR Paradigm activates first Aus site for osteoarthritis drug trials Paradigm Biopharmaceuticals Ltd has opened its first Australian site as part of a trial to assess injectable pentosan polysulfate sodium Caroline Smith 03 Jun 2025 12:08 (AEST) ASX News Healthcare Biotechnology
CDX Cardiex wins TGA greenlight; shares jump +11% Cardiex Ltd (ASX:CDX) has popped +11% intraday to 4.7cps as the smallcap healthcare stock wins a key approval from the TGA. Jonathon Davidson 02 Jun 2025 11:47 (AEST) ASX News Healthcare Technology Scientific & Technical Instruments
DXB Dimerix launches key trial in Japan as recruitment kicks off Dimerix (ASX:DXB) has kicked off a key trial in Japan (in terms of patient recruitment) seeking to treat inflammatory diseases. Jonathon Davidson 30 May 2025 11:08 (AEST) ASX News Healthcare Biotechnology
BP8 BP8 ships first Indonesian seaweed under cornerstone partnership BP8 Global Ltd has made its first shipment of Indonesian seaweed to a South Korean food ingredient manufacturer Caroline Smith 29 May 2025 14:09 (AEST) ASX News Agriculture Consumer Cyclical Healthcare Biotechnology
RNV ReNerve snaffles approval in Bahrain, looks to expand throughout the ME ReNerve Ltd has received marketing approval from Bahrain which will see its nerve repair devices commercialised throughout the country Caroline Smith 28 May 2025 13:21 (AEST) ASX News Healthcare Steel Medical Devices Basic Materials
AFP Reshaped Combogesic deal sets 'pleased' AFT Pharma up to answer US demand New Zealand drug maker AFT Pharmaceuticals (ASX:AFP) will continue working with United States distributor Hikma Pharmaceuticals to sell key products in the U.S. after the two biotech companies put pen to paper on a new deal.Listen to the HotCopper podcast for in-depth discussions and insights on ... Isaac McIntyre 26 May 2025 14:56 (AEST) ASX News Healthcare Biotechnology
MYX Mayne Pharma nosedive deepens as Cosette mulls scrapping $672M buy-up Mayne Pharma Group (ASX:MYX) has been taking a beating in the markets this week, with company value as much as -33% lower @ today down to $4.34 a share after opening Week 21 at $6.48 @ on second thoughts from Cosette.Listen to the HotCopper podcast for in-depth discussions and insights on all the... Isaac McIntyre 22 May 2025 15:23 (AEST) ASX News Healthcare Drug Manufacturers - Specialty & Generic
AFP AFT Pharma sets new $300M target after reaching $200M revenue for FY25 AFT Pharmaceuticals Ltd has unveiled its financial results for FY2025, announcing that it has reached a revenue of more than $200M Caroline Smith 22 May 2025 09:33 (AEST) ASX News The Watchlist Healthcare Biotechnology
PAR This stock could have something close to a cure for osteoarthritis. Don’t let it hide under your nose Paradigm Biopharmaceuticals (ASX:PAR) is a late-stage drug development company working first and foremost to create a superior treatment for osteoarthritis.In the background, Paradigm also has a rare disease clinal asset for Mucopolysaccharidosis (MPS) and early-stage data for acute respiratory d... Jonathon Davidson 21 May 2025 08:34 (AEST) ASX News Healthcare Biotechnology